search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Cell Culture


Figure 2


Live (green) and dead (red) stained 96-hour mono- and


co-culture A549 and fibroblast spheroids. Spheroids were exposed to high (34.5µM) and low (27.6µM) doses of


doxorubicin or vehicle control (no doxorubicin) for 48 hours in Corning 384-well spheroid microplates. Fibroblast (FB) monoculture displayed the most intense live staining upon low dose exposure to


doxorubicin, while A549 monoculture showed


increased cell death. The 9:1 ratio of FB to A549 cells also displayed a protective effect at the low-dose doxorubicin exposure. All cell types


displayed significant toxicity after high dose exposure. Images captured using an


EVOS fluorescent microscope at 10x objective. Scale bar = 400µm


microplate. Cell viability was assessed using CellTiter-Glo 3D cell viability assay and the lumi- nescent signal from samples were plotted as per- cent compared to vehicle control to generate dose response curves (Figure 3). Toxicity potency


(TC50) values were calculated and compared across the spheroid culture conditions (Table 1). Although the presence of FB and immune cells did not affect the potency of compounds carboplatin and cisplatin to A549 lung tumour cells, a right- shift in the potency of several other known chemotherapeutics was observed, demonstrating the protective effects of the presence of other cell types such as FB in a co-culture spheroid.


Co-culture with endothelial cells In this study, an epithelial tumour cell line was cultured in 96-well Corning spheroid microplates with and without the presence of GFP-expressing mouse endothelial C166 cells. Tumour spheroid viability was screened after treatment with vari- ous chemotherapeutics in both single tumour cell line culture and endothelial co-culture conditions. Dose-dependent responses of selected chemother- apeutics were compared, demonstrating the importance of including multiple cell types in 3D assays to more closely mimic the in vivo tumor microenvironment.


44


Spheroid formation HT-29 (ATCC® Cat. No. HTB-38) and C166-GFP (ATCC Cat. No. CRL-2583) were cultured in 2D format following ATCC’s protocols. Confluent cells were harvested and seeded into 96-well spheroid microplates (Corning Cat. No. 4520) at 2,000 total cells per well either in mono-culture or in co-culture with a seeding ratio of 1:1. Cells were seeded in 100µL per well of culture medium (IMDM [Corning Cat. No. 10-016-CM] supple- mented with 10% FBS [Corning Cat. No. 35-010- CV]). Cells were cultured in a humidified 37˚C,


5% CO2 incubator for 24 hours for the formation of a spheroid in each well. After 24 hours the spheroids were overlaid with 100µL per well of 1.76mg/mL Corning Matrigel matrix (Corning Cat. No. 354234) diluted in culture medium. The Corning spheroid microplates were centrifuged at 220 x g at 4˚C for two minutes and returned to a humidified 37˚C, 5% CO2 incubator for four days.


Cell viability assays


Five days after cell seeding, 50µL per well of com- pounds in culture medium containing 0.5% dimethyl sulfoxide (DMSO) (Corning Cat. No. 25- 950-CQC) were added. 50µL of culture medium containing 0.5% DMSO was used as vehicle con- trol. Spheroids were cultured for an additional 48


Drug Discovery World Winter 2017/18


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72